Evidence map›Paper›PMID 32750707›Full record

Trial reportBlood2020

Identification of occult cerebral microbleeds in adults with immune thrombocytopenia.

Nichola Cooper, Melanie A Morrison, Camelia Vladescu, Alice C J Hart, Deena Paul, Amna Malik, Thomas Young, Asad Luqmani, Maria Atta, David J Sharp and 2 more

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Refractory ITP: revisiting definitions, diagnostics, and management paradigms.Hematology. American Society of Hematology. Education Program · 2025
    Review
  6. Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress.Research and practice in thrombosis and haemostasis · 2024
    Article
  7. How we treat primary immune thrombocytopenia in adults.Journal of hematology & oncology · 2023
    Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Nichola CooperDepartment of Haematology, Hammersmith Hospital, London, United Kingdom.
Melanie A MorrisonDepartment of Medicine and.
Camelia VladescuDepartment of Haematology, Hammersmith Hospital, London, United Kingdom.
Alice C J HartDepartment of Haematology, Hammersmith Hospital, London, United Kingdom.
Deena PaulDepartment of Haematology, Hammersmith Hospital, London, United Kingdom.
Amna MalikDepartment of Medicine and.
Thomas YoungDepartment of Haematology, Hammersmith Hospital, London, United Kingdom.
Asad LuqmaniDepartment of Haematology, Hammersmith Hospital, London, United Kingdom.
Maria AttaDepartment of Haematology, Hammersmith Hospital, London, United Kingdom.
David J SharpDepartment of Brain Sciences, Imperial College, London, United Kingdom.
James B BusselWeil-Cornell Medical Centre, New York Presbyterian Hospital, New York, NY; and.
Adam D WaldmanDepartment of Brain Sciences, Imperial College, London, United Kingdom.
Hammersmith Hospital · GBImperial College London · GBNewYork–Presbyterian Hospital · US

Funding

Department of Health NIHR-RP-011-048
6 · The paper itself

Abstract

Management of symptoms and prevention of life-threatening hemorrhage in immune thrombocytopenia (ITP) must be balanced against adverse effects of therapies. Because current treatment guidelines based on platelet count are confounded by variable bleeding phenotypes, there is a need to identify new objective markers of disease severity for treatment stratification. In this cross-sectional prospective study of 49 patients with ITP and nadir platelet counts <30 × 109/L and 18 aged-matched healthy controls, we used susceptibility-weighted magnetic resonance imaging to detect cerebral microbleeds (CMBs) as a marker of occult hemorrhage. CMBs were detected using a semiautomated method and correlated with clinical metadata using multivariate regression analysis. No CMBs were detected in health controls. In contrast, lobar CMBs were identified in 43% (21 of 49) of patients with ITP; prevalence increased with decreasing nadir platelet count (0/4, ≥15 × 109/L; 2/9, 10-14 × 109/L; 4/11, 5-9 × 109/L; 15/25 <5 × 109/L) and was associated with longer disease duration (P = 7 × 10-6), lower nadir platelet count (P = .005), lower platelet count at time of neuroimaging (P = .029), and higher organ bleeding scores (P = .028). Mucosal and skin bleeding scores, number of previous treatments, age, and sex were not associated with CMBs. Occult cerebral microhemorrhage is common in patients with moderate to severe ITP. Strong associations with ITP duration may reflect CMB accrual over time or more refractory disease. Further longitudinal studies in children and adults will allow greater understanding of the natural history and clinical and prognostic significance of CMBs.

Indexed as

Cerebral HemorrhageMagnetic Resonance ImagingNeuroimagingPurpura, Thrombocytopenic, IdiopathicAdultAgedAged, 80 and overCross-Sectional StudiesFemaleHumansMaleMiddle AgedPlatelet CountProspective Studies

Identifiers

PMID32750707
PMCPMC7751366
OpenAlexW3047204348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.